Novartis begins filings for cannabis-based Sativex in Middle East
This article was originally published in Scrip
Executive Summary
Novartis will target filings in the Middle East next as part of its licence agreement with GW Pharmaceuticals for the cannabis-based multiple sclerosis-related spasticity treatment Sativex. These are slated for the first half of 2012, GW's managing director Justin Gover told Scrip.